Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.

Neil M BresslerMiroslav VeithJan HamouzJan ErnestDominik ZalewskiJan StudničkaAttila VajasAndrás PappGabor VogtJames LuuVeronika Matušková Young Hee YoonTamás PregunTaehyung KimDonghoon ShinInkyung OhHansol JeongMercy Yeeun KimSe Joon Woo

Published in: The British journal of ophthalmology (2021)

Longer-term results of this study further support the biosimilarity established between SB11 and RBZ.

Keyphrases

age related macular degeneration
clinical trial
phase iii
open label
double blind
phase ii
placebo controlled
study protocol
preterm infants
metabolic syndrome
randomized controlled trial
skeletal muscle
optical coherence tomography
adipose tissue